Skip to main content

Baxter International Value Stock - Dividend - Research Selection

Baxter international

ISIN: US0718131099 , WKN: 853815

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Baxter International Inc. provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. The company also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors\' offices, and by patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Baxter Showcases Recent Innovations at AORN Global Surgical Conference & Expo 2026

2026-04-13
Highlights include the AAT XR, the next-generation version of the Allen Advance Table designed to support surgical teams across a range of spine procedures, and the Dynamo Series smart stretcher...

Alpha Buying: Following Conviction, Not the Crowd

2026-04-09

Baxter to Host First-Quarter 2026 Financial Results Conference Call for Investors

2026-04-08
DEERFIELD, Ill., April 08, 2026--Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its first-quarter 2026 financial results on Thursday, April 30, 2026 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I946023356 to pre-register for the call and receive the call information.

Hologic hires former Baxter leader José Almeida as CEO

2026-04-08
The company appointed Almeida as chief executive in conjunction with the completion of an $18.3 billion go-private deal.

2 Oversold Stocks Set for a Comeback and 1 We Brush Off

2026-04-07
The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling knives.

Evercore ISI Group Maintains Outperform on Baxter International, Lowers Price Target to $22

2026-04-06
Evercore ISI Group analyst Vijay Kumar maintains Baxter International (NYSE:BAX) with a Outperform and lowers the price target from $23 to $22.

How Investors May Respond To Baxter International (BAX) Expanding Into Automated IV Line Labeling Systems

2026-04-04
Baxter International has launched the IV Verify Line Labeling System in the U.S. after debuting it at the 2026 American Organization for Nursing Leadership Conference, offering an automated way to print standardized, color‑coded IV tubing labels that integrate barcodes, timing details, and patented ink‑free technology. The exclusive distribution agreement with Vigilant Software positions Baxter more firmly in medication safety automation, targeting persistent IV line labeling errors that can...

Baxter International Inc. stock outperforms competitors on strong trading day

2026-03-31
Baxter International Inc. stock outperforms competitors on strong trading day

Baxter International Unveils IV Verify to Enhance IV Labeling Accuracy

2026-03-31
BAX introduces the IV Verify system to improve IV labeling accuracy, targeting medication safety gaps and boosting workflow efficiency in clinical settings.

Inogen Announces Leadership Appointments Designed to Accelerate Next Phase of Growth

2026-03-30
BEVERLY, Mass., March 30, 2026--Inogen Announces Leadership Appointments Designed to Accelerate Next Phase of Growth